Sharp Therapeutics (TSXV:SHRX) OCF Margin %: 0.00% (As of Dec. 2025)


TSXV:SHRX Sharp Therapeutics Corp TSXV:SHRX
15 GF Score
Price C$0.91
View Full Analysis

What is Sharp Therapeutics OCF Margin %?

Sharp Therapeutics TSXV:SHRX -9.00% 15 OCF Margin % is 0.00% as of Dec. 2025. GuruFocus rates TSXV:SHRX with a GF Score™ of 15/100. Among 956 Biotechnology companies, Sharp Therapeutics ranks worse than 104602.41% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Sharp Therapeutics's Cash Flow from Operations for the three months ended in Dec. 2025 was C$-1.35 Mil. Sharp Therapeutics's Revenue for the three months ended in Dec. 2025 was C$0.00 Mil. Therefore, Sharp Therapeutics's OCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

As of today, Sharp Therapeutics's current OCF Yield % is -22.38%.

The historical rank and industry rank for Sharp Therapeutics's OCF Margin % or its related term are showing as below:


TSXV:SHRX's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -68.59
* Ranked among companies with meaningful OCF Margin % only.

Sharp Therapeutics OCF Margin % Related Terms

Sharp Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Sharp Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sharp Therapeutics OCF Margin % Chart

Sharp Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
OCF Margin %
0.00 0.00 0.00

Sharp Therapeutics Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
OCF Margin % Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSXV:SHRX
15GF Score
Sharp Therapeutics Corp TSXV:SHRX
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sharp Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Sharp Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-6.664/0
= %

Sharp Therapeutics's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-1.346/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Sharp Therapeutics (TSXV:SHRX) has a OCF Margin % of 0.00% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Sharp Therapeutics and its competitors. According to the industry distribution chart, Sharp Therapeutics ranks #999999 out of 956 companies in the Biotechnology industry.
Is Sharp Therapeutics' OCF Margin % too high?
Sharp Therapeutics' current OCF Margin % is 0.00%. Based on the distribution chart, Sharp Therapeutics ranks #999999 out of 956 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sharp Therapeutics has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Sharp Therapeutics' OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sharp Therapeutics ranks #999999 out of 956 companies for OCF Margin %. This places Sharp Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Sharp Therapeutics and its competitors. Sharp Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sharp Therapeutics stock overvalued right now?
Sharp Therapeutics (TSXV:SHRX) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Sharp Therapeutics' overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Sharp Therapeutics (TSXV:SHRX), the current OCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sharp Therapeutics Business Description

Address 2403 Sidney Street, Suite 264, Pittsburgh, PA, USA, 15203
Sharp Therapeutics Corp is a preclinical-stage drug discovery company developing therapeutics for genetic diseases. It has developed the patent-protected Disco discovery platform consisting of the CoreX biology, AlloChem chemistry, and Mine computational technologies to discover drugs that selectively activate the protein thats been altered by gene mutation. The company has targeted its discovery engine (Disco) to three hereditary disorders with high unmet need, which include Gauchers Disease, Familial Frontotemporal Dementia, and Niemann Pick Type-C. Its drug development pipeline consists of the following candidates: SEL-148, 721, SEL-148, 742, and SEL-145, 793. Geographically, the company's business operations are carried out in the United States of America.
15GF Score

Get the complete analysis for TSXV:SHRX

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.91
Price